ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
ANGO - AngioDynamics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$19.50
DETAILS
HIGH:
$20.00
LOW:
$19.00
MEDIAN:
$19.50
CONSENSUS:
$19.50
UPSIDE:
57.70%
Stock News
AngioDynamics Stock Is Falling Thursday: What's Going On?
AngioDynamics Inc. (NASDAQ:ANGO) stock plunged more than 21% Thursday despite reporting better-than-expected first-quarter financial results.
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q1 2027 Earnings Call Transcript
Why AngioDynamics Crashed Today
AngioDynamics beat on both top and bottom lines this morning. The company still lost $0.04 per share, pro forma, and its GAAP loss was four times bigger.
AngioDynamics Q1 Earnings Call Highlights
AngioDynamics NASDAQ: ANGO reported fiscal 2027 first-quarter revenue growth of 6.9% to $80.9 million, led by continued expansion in its Med Tech segment, while the company maintained its full-year outlook and announced that Eric Honroth will become president and chief executive officer effective Nov. 2.
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.
AngioDynamics (NASDAQ:ANGO) Announces FY 2027 Earnings Guidance
AngioDynamics (NASDAQ: ANGO - Get Free Report) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share guidance of -0.290-0.240 for the period, compared to the consensus EPS estimate of -0.260. The company issued revenue guidance of $336.0 million-$341.0 million, compared to the consensus revenue estimate of $337.6 million. AngioDynamics Trading Down
AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2027, which ended August 31, 2026. Fiscal Year 2027 First Quarter Financial Highlights Quarter Ended August 31, 2026 YoY Growth Net Sales $80.9 million.
AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on N.
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that Dr. Jonathan Alis, Dr. Seth I. Sokol and their team at Jacobi Hospital in Bronx, New York have been selected as an ALPHA-PE Research Fund award recipients. The independent, investigator-led study, supported in partnership with The PERT C.
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To pa.
32,900 Shares in AngioDynamics, Inc. $ANGO Acquired by Canada Pension Plan Investment Board
Canada Pension Plan Investment Board purchased a new position in shares of AngioDynamics, Inc. (NASDAQ: ANGO) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 32,900 shares of the medical instruments supplier's stock, valued at approximately $428,000. Canada Pension Plan
AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE
Bank of America Corp DE grew its holdings in shares of AngioDynamics, Inc. (NASDAQ: ANGO) by 262.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 503,640 shares of the medical instruments supplier's stock after purchasing an additional 364,763
AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?
AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027
AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.
Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?
AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.
ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus
AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.
ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?
AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.
AngioDynamics to Participate in Upcoming Investor Conferences
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular syste
AngioDynamics to Participate in Upcoming Investor Conferences
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.
Price Targets
AngioDynamics price target raised to $19 from $16 at H.C. Wainwright
$19.00
(was $14.49)
Yi Chen
·
H.C. Wainwright
AngioDynamics price target raised to $20 from $16 at Canaccord
$20.00
(was $13.00)
Canaccord Genuity
AngioDynamics price target raised to $18 from $17 at Canaccord
$18.00
(was $11.74)
Canaccord Genuity
AngioDynamics price target raised to $17 from $15 at Canaccord
$17.00
(was $8.72)
John Young
·
Canaccord Genuity
AngioDynamics (ANGO) PT Lowered to $12 at Canaccord Genuity
$12.00
(was $6.10)
William Plovanic
·
Canaccord Genuity
H.C. Wainwright Reiterates Buy Rating on AngioDynamics (ANGO)
$14.00
(was $7.70)
Yi Chen
·
H.C. Wainwright
AngioDynamics upgraded to Outperform from Perform at Oppenheimer
$12.00
(was $6.40)
Steven Lichtman
·
Oppenheimer
Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $22
$22.00
(was $15.48)
Raymond James
Raymond James Maintains Strong Buy on AngioDynamics, Lowers Price Target to $27
$27.00
(was $20.02)
Raymond James